Regeneron Pharmaceuticals, Inc. Financials

Market Capitalization $76.33 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	17.18
Forward PE	15.33
Price to Sales TTM	$5.51
Price to Book MRQ	$2.55
Enterprise to Revenue	4.89
Enterprise to EBITDA	14.71

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	33.61%
Operating Margin	33.43%
Return on Assets TTM	7.41%
Return on Equity TTM	17.17%

Income Statement

Revenue TTM	$13,847,100,416
Revenue per Share TTM	$128.69
Quarterly Revenue Growth	10.60%
Gross Profit TTM	$7,027,899,904
EBITDA	$5,243,100,000
Net Income to Common TTM	$4,654,499,840
Diluted EPS TTM	$40.43
Quarterly Earnings Growth YoY	33.00%

Balance Sheet

Total Cash MRQ	$9,796,500,480
Total Cash per Share MRQ	$91.05
Total Debt MRQ	$
Total Debt to Equity MRQ	9.22
Current Ratio MRQ	5.28
Book Value per Share MRQ	$272.04

Cash Flow

Operating Cash Flow TTM	$4,247,399,936
Levered Free Cash Flow TTM	$2,247,637,504

REGN Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	108,072,000
Float Shares	103,101,972
Avg 10 Volume	1,015,530
Avg 30 Volume	None
Shares Short	2,095,552
Short Ratio	2.44
Short % of Shares	2.01%
% Held by Insiders	1.57%
% Held by Institutions	90.71%

Stock Price Summary

Beta	0.14
Fifty Two Week Low	$666.25
Fifty Two Week High	$1211.20
Fifty Two Week Change	-41.43%
Day 50 MA	$738.09
Day 200 MA	$955.55

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date